Novavax’s COVID-19 Vaccine Boost From First Phase I Data
Executive Summary
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
You may also be interested in...
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Coronavirus Update: Novavax Launches Phase III Trial In UK As Virus Surges Back
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.